Drugs / ALVAC MART-1 Vaccine
ALVAC MART-1 Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00706992 | Jun 2008 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00612222 | Jan 2008 → Mar 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC MART-1 vaccine | “Starting with amendment E, the four cohorts above will be closed to accrual and patients will be randomized to the following cohorts: 5. F5 cells on day 0 following...” NCT00706992 ↗ |
| Known as | ALVAC vaccine | “Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50” NCT00706992 ↗ |
| Known as | plaque purified canarypox vector (ALVAC) MART-1 | “The treatment procedure also uses a vaccine called plaque purified canarypox vector (ALVAC) MART-1, made from a virus that ordinarily infects canaries and is modified to carry...” NCT00612222 ↗ |
| Modality | Vaccine | “a vaccine called plaque purified canarypox vector (ALVAC) MART-1” NCT00612222 ↗ |
| Route | Subcutaneous | “Given subcutaneously” NCT00706992 ↗ |